Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Mechaniczna stymulacja donosowa (INMEST) jako potencjalne leczenie zapobiegawcze migreny (A-MI-01)

2 listopada 2026 zaktualizowane przez: Abilion Medical Systems AB

Mechaniczna stymulacja donosowa (INMEST) jako potencjalne leczenie profilaktyczne migreny – prospektywne, randomizowane, otwarte, opóźnione badanie mające na celu ocenę bezpieczeństwa i skuteczności systemu Walther

This is a prospective, randomized, open-label, delayed-start clinical investigation evaluating the safety and efficacy of the Walther System, a Class IIa investigational medical device delivering intra-nasal mechanical stimulation (INMEST), as a preventative treatment for migraine. A total of 110 adults (18-65 years) with a history of migraine will be randomized 1:1 into two groups: Group A (early treatment) and Group B (delayed treatment). The study includes baseline assessments, in-clinic device training, and home-based self-administered treatments every second day for six weeks. The primary outcome is the change in monthly migraine days during the primary treatment comparison period. Secondary outcomes include headache days, migraine intensity, duration, rescue medication use, patient-reported outcomes, device compliance, and safety. The study will be conducted at one site in Sweden.

Przegląd badań

Status

Aktywny, nie rekrutujący

Warunki

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Szacowany)

110

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

      • Stockholm, Szwecja, 11327
        • INMEST-mottagningen Odenplan

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 65 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  1. Age 18-65 years at the time of screening.

  2. The study subject must have a clinical diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-3), indicated by medical record shown by the subject.

  3. Onset of migraine headache occurred before age 50.

  4. History of migraines for at least 1 year before screening.

  5. The study subject reports at least 8 monthly migraine days during the screening period.

  6. If subject is on a prophylactic migraine medication regimen:

    1. Reports stable medication regimen during the three months prior to screening.
    2. Able and willing to maintain medication regimen (no change in type, frequency or dose) from screening to end of follow-up.
  7. The study subject reports having understood and have signed the Informed Consent Form (ICF) and is willing to comply with all investigation visits and assessments.

  8. Women of childbearing potential must agree to use a reliable, medically approved form of contraception during the study participation until end of study.

  9. Anticipated compliance with prescribed treatment and follow-up.

Exclusion Criteria:

  1. Subject unable to distinguish between migraine headaches and other headache types.
  2. Recently (12 months prior screening) undergone nasal or sinus surgery.
  3. Any severe diseases for which, in the opinion of the Investigator, participation would not be in the best interest of the subject or that can interfere with the performance, evaluation, and outcome of the clinical evaluation.
  4. Previous (within 30 days prior to screening) and concurrent treatment with another investigational drug/s or device/s.
  5. Subject is pregnant or lactating or planning to get pregnant during the duration of the study.
  6. The study subject has a cognitive incapacity or language barrier precluding adequate understanding or cooperation.
  7. The study subject is considered by the Investigator to be unsuitable to participate in the investigation for any other reason.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Aktywny komparator: Group A - Early Start

Subjects undergo a 4-week baseline assessment (weeks 1-4), then receive active treatment with the Walther System every second day for 6 weeks (weeks 5-10). The first treatment is performed under supervision at the clinic, and subsequent treatments are self-administered at home. Post-treatment assessments occur during weeks 11-14.

Hand-held controller and catheter assembly for intra-nasal mechanical stimulation (INMEST), self-administered at home every second day for 6 weeks, first treatment under supervision.

Inne nazwy:
  • System Walthera
Aktywny komparator: Group B - Delayed Start

Subjects undergo a 4-week baseline assessment (weeks 1-4), followed by a 6-week no-treatment reference period (weeks 5-10). Active treatment with the Walther System is then administered every second day for 6 weeks (weeks 11-16), starting with an initial supervised treatment at the clinic. Post-treatment assessments occur during weeks 17-20.

Hand-held controller and catheter assembly for intra-nasal mechanical stimulation (INMEST), self-administered at home every second day for 6 weeks, first treatment under supervision.

Inne nazwy:
  • System Walthera

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Change in Monthly Migraine Days
Ramy czasowe: Weeks 7-10 (Group A: Treatment performance period; Group B: No treatment reference period)

Between-group comparison of the difference in mean change in monthly migraine days from the baseline assessment period (weeks 1-4) to Group A) Treatment performance period (weeks 7-10) and Group B) No treatment reference period (weeks 7-10).

Weeks 7-10 (Group A: Treatment performance period; Group B: No treatment reference period)

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Mean change in monthly headache days
Ramy czasowe: Weeks 7-10

Between-group comparison of the difference in mean change in monthly headache days from baseline.

Weeks 7-10
Mean change in migraine intensity
Ramy czasowe: Weeks 7-10

Between-group comparison of the difference in mean change in migraine intensity from baseline.

Weeks 7-10
Mean change in duration of migraine attacks
Ramy czasowe: Weeks 7-10

Between-group comparison of the difference in mean change in migraine attack duration (hours) from baseline.

Weeks 7-10
Proportion of attacks requiring rescue medication
Ramy czasowe: Weeks 7-10

Between-group comparison of the proportion of migraine attacks requiring rescue medication.

Weeks 7-10
Number of participants with ≥30% and ≥50% reduction in monthly migraine days
Ramy czasowe: Weeks 7-10

Between-group comparison of the proportion of subjects achieving ≥30% and ≥50% reduction in monthly migraine days.

Weeks 7-10
Mean change in PROMIS-PI SF-6b
Ramy czasowe: Weeks 7-10

Between-group comparison of the difference in mean change from baseline in PROMIS-PI SF-6b scores. The raw scores are converted to standardized T-scores (range 0-100; mean = 50, SD = 10) based on the PROMIS calibration sample. Higher scores indicate greater pain-related interference.

Weeks 7-10
Mean change in Migraine-Specific Quality of Life Questionnaire (MSQ)
Ramy czasowe: Weeks 7-10

Between-group comparison of the difference in mean change from baseline in MSQ scores. Scores are transformed to a 0-100 scale, with higher scores indicating better quality of life.

Weeks 7-10
Mean change in Patient Global Impression of Severity (PGI-S)
Ramy czasowe: Weeks 7-10

Between-group comparison of the difference in mean change from baseline in PGI-S scores. Measured on a 7-point scale (1 = least severe, 7 = most severe), where higher values indicate greater severity.

Weeks 7-10
Mean change in monthly migraine days
Ramy czasowe: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in monthly migraine days within each group.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in monthly headache days
Ramy czasowe: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in monthly headache days within each group.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in migraine intensity (6-point severity scale)
Ramy czasowe: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in migraine intensity within each group. Migraine intensity is assessed using a 6-point severity scale (1 = Very mild, 6 = Very severe), where higher scores indicate greater pain severity.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in duration of migraine attacks
Ramy czasowe: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in duration of migraine attacks (hours) within each group.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Proportion of migraine attacks requiring rescue medication
Ramy czasowe: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Proportion of migraine attacks requiring rescue medication within each group.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Number of participants with ≥30% and ≥50% reduction in monthly migraine days
Ramy czasowe: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Proportion of subjects achieving ≥30% and ≥50% reduction in monthly migraine days within each group.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in PROMIS-PI SF-6b
Ramy czasowe: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in PROMIS-PI SF-6b scores within each group. The raw scores are converted to standardized T-scores (mean = 50, SD = 10) based on the PROMIS calibration sample. Higher scores indicate greater pain-related interference.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in Migraine-Specific Quality of Life Questionnaire (MSQ)
Ramy czasowe: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in PROMIS-PI SF-6b, MSQ, and PGI-S scores within each group. Scores are transformed to a 0-100 scale, with higher scores indicating better quality of life.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in Patient Global Impression of Severity (PGI-S)
Ramy czasowe: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in PGI-S scores within each group. Measured on a 7-point scale (1 = least severe, 7 = most severe), where higher values indicate greater severity.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in monthly migraine days
Ramy czasowe: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in monthly migraine days, pooled across both groups.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in monthly headache days
Ramy czasowe: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in monthly headache days, pooled across both groups.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in migraine intensity (6-point severity scale)
Ramy czasowe: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in migraine intensity, pooled across both groups. Migraine intensity is assessed using a 6-point severity scale (1 = Very mild, 6 = Very severe), where higher scores indicate greater pain severity."

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in duration of migraine attacks
Ramy czasowe: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in duration of migraine attacks (hours), pooled across both groups.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Proportion of migraine attacks requiring rescue medication
Ramy czasowe: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Proportion of migraine attacks requiring rescue medication, pooled across both groups.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Number of participants with ≥30% and ≥50% reduction in monthly migraine days
Ramy czasowe: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Proportion of subjects achieving ≥30% and ≥50% reduction in monthly migraine days, pooled across both groups.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in PROMIS-PI SF-6b
Ramy czasowe: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in PROMIS-PI SF-6b scores, pooled across both groups. The raw scores are converted to standardized T-scores (mean = 50, SD = 10) based on the PROMIS calibration sample. Higher scores indicate greater pain-related interference.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in Migraine-Specific Quality of Life Questionnaire (MSQ)
Ramy czasowe: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in PROMIS-PI SF-6b, MSQ, and PGI-S scores, pooled across both groups. Scores are transformed to a 0-100 scale, with higher scores indicating better quality of life.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in Patient Global Impression of Severity (PGI-S)
Ramy czasowe: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in PGI-S scores, pooled across both groups. Measured on a 7-point scale (1 = least severe, 7 = most severe), where higher values indicate greater severity.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Proportion of prescribed treatments completed
Ramy czasowe: Throughout the 6-week treatment period

Compliance based on device usage logs or participant-reported treatment diaries.

Throughout the 6-week treatment period
Adverse Events / Serious Adverse Events / Device Effects
Ramy czasowe: Through study completion (14 or 20 weeks, depending on treatment group)

Number of treatment-related AEs, SAEs, ADEs, SADEs, and Unanticipated SADEs for the Walther System.

Through study completion (14 or 20 weeks, depending on treatment group)
Device Deficiencies
Ramy czasowe: Throughout the 6-week treatment period

Number of device deficiencies for the Walther System.

Throughout the 6-week treatment period

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Device usability and user experience (combined questionnaires)
Ramy czasowe: Throughout the 6-week treatment period

User-reported usability, ease of use, handling, and overall experience of the device during home use, assessed using two Device Usability Questionnaires. Questions include multiple 3- or 5-point scales, 0-10 scales, and yes/no responses. Higher scores indicate better usability or greater interest where applicable.

Throughout the 6-week treatment period
Symptom trends (Symptom Questionnaire)
Ramy czasowe: Throughout the 6-week treatment period

Changes in symptoms potentially related to autonomic nervous system function, assessed using the Symptom Questionnaire at Visits 1-5. The questionnaire includes multiple items with 0-6 and 0-3 ordinal scales, yes/no responses, and other response formats. Higher scores indicate more severe symptoms."

Throughout the 6-week treatment period

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Współpracownicy

Śledczy

  • Główny śledczy: Jan-Erik Juto, PhD, MD

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

21 października 2025

Zakończenie podstawowe (Szacowany)

1 listopada 2026

Ukończenie studiów (Szacowany)

1 listopada 2026

Daty rejestracji na studia

Pierwszy przesłany

18 listopada 2025

Pierwszy przesłany, który spełnia kryteria kontroli jakości

10 grudnia 2025

Pierwszy wysłany (Rzeczywisty)

12 grudnia 2025

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

3 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

2 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • A-MI-01
  • CIV-25-05-052936 (Identyfikator rejestru: Swedish Clinical Trials Registry)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .